| dc.creator |
Covic, Adrian |
|
| dc.creator |
Kuwabara, Masanari |
|
| dc.creator |
Sag, Alan A. |
|
| dc.creator |
Oztosun, Cinar |
|
| dc.creator |
Sanli, Sueda |
|
| dc.creator |
Acar, Simge |
|
| dc.creator |
Ortiz, Alberto |
|
| dc.creator |
Kanbay, Mehmet |
|
| dc.creator |
AFŞAR, Barış |
|
| dc.date |
2021-01-01T00:00:00Z |
|
| dc.date.accessioned |
2021-12-03T11:28:49Z |
|
| dc.date.available |
2021-12-03T11:28:49Z |
|
| dc.identifier |
549e1699-fe9a-4b9d-aa55-f2798ed72e09 |
|
| dc.identifier |
10.1007/s11255-020-02704-7 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/549e1699-fe9a-4b9d-aa55-f2798ed72e09/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/91899 |
|
| dc.description |
Diuretic volume reduction continues to be the mainstay of congestive heart failure (CHF) management globally. However, diuretic resistance is a critical topic that lacks standardized evidence-based management guidelines accounting for mechanisms of diuretic resistance, renal function, and co-morbidities. Major healthcare utilization consequences result from this. The authors herein reconcile the definition of renal functional decline with emphasis on biomarker-driven assessment. Novel goal-directed treatment approaches are reviewed including hypertonic saline, acetazolamide, sodium-glucose transporter inhibition, sequential nephron blockade and Elabela-APJ axis targeting are reviewed, as well as percutaneous visceral splanchnic sympathectomy (converting a volume-focused to a distribution-focused paradigm). |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review |
|
| dc.type |
info:eu-repo/semantics/article |
|